Trial Profile
A Phase 1 Dose Finding Study of the Safety and Pharmacokinetics of XL184 Administered Orally in Combination With Temozolomide and Radiation Therapy in the First Line Treatment of Subjects With Glioblastoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2015
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- Sponsors Exelixis
- 20 Nov 2015 Results published in the Cancer
- 19 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Feb 2013 Planned End Date changed from 1 Dec 2011 to 1 Apr 2013 as reported by ClinicalTrials.gov.